<DOC>
	<DOC>NCT00729404</DOC>
	<brief_summary>Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers</brief_summary>
	<brief_title>Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene</brief_title>
	<detailed_description>Study was suspended due to inconclusive toxicology findings regarding the used patch formulation to be clarified prior to re-start of the study.</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Femovan</mesh_term>
	<criteria>Signed informed consent, BMI: 18 30 kg/mÂ², Healthy female volunteers, Age 1835 years (smoker not older than 30 years, inclusive), Ovulatory pretreatment cycle, at least 3 month since delivery, Abortion or lactation before the first screening examination, Willingness to use nonhormonal methods of contraception during entire study Contraindications for use of combined (estrogen/gestodene) contraceptive (e.g. history of venous/arterial thromboembolic disease Regular intake of medication other than OCs Clinically relevant findings (blood pressure, physical and gynaecological examination, laboratory examination) Anovulatory pretreatment cycle</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Female Contraception</keyword>
	<keyword>Ovulation Inhibition</keyword>
</DOC>